





Α.



## Lipid raft purification after inhibition of palmitoylation



## **Supporting Information**

**S. Figure 1. Only TM and ICD (without ECD) is enough for aggregation.** (A) Schematic image of full length and the different truncated mutants of hSiglec-11. (B) HEK293 cells were transiently transfected with V5-tagged full length hSiglec-11 or truncated mutant (TM) and cell lysates were analyzed by Western blotting under reducing (left panel) and non-reducing condition (right panel) with anti-V5 tag antibody. Lysates were heated to 100 °C for 5 minutes. fMock indicates transfection without the plasmid.

S. Figure 2. Inhibition of hSiglec-11(5D) ECD proteolytic cleavage. HEK293 cells were transiently transfected with V5-tagged full length hSiglec-11(5D) for 2 days, then DMSO or one of the inhibitors (PIC, GM6001 or KMI-1303) was added. Cells were harvested on Day 3. Cell lysates were analyzed by Western blotting under reducing condition with anti-V5 tag antibody. Expression levels of full length Siglec-11 (higher molecular weight membrane) and proteolytical fragment (lower molecular weight) were different, requiring different exposures.  $\beta$ -actin was used as loading control. Mock indicates transfection without the plasmid.

**S. Figure 3. Recognition epitope of 4C4 antibody on Siglec-11.** HEK293 cells were transiently transfected with V5-tagged full length hSiglec-11 or truncated mutants and cell lysates were analyzed by Western blotting under reducing condition with either anti-V5 tag antibody (**A**) and 4C4 antibody (**B**).

**S. Figure 4. Effect of palmitoylation on hSiglec-11 for lipid raft localization.** Cell lysates of V5-tagged Siglec-11 transfected HEK293 cells cultured with or without 2BP were fractionated by density gradient separation and analyzed by Western blotting with anti-V5 tag antibody. The left panel is hSiglec-11(5D) without 2BP and the right panel is hSiglec-11(5D) with 2BP. Flotillin-1 was used as a lipid raft marker.